Background
Among an aging population the prevalence of heart failure (HF) continues to rise, as it is estimated nearly 6.2 million adults in the United States are afflicted with this condition.
The financial impact of this disease also places a significant burden on patients and healthcare resources, accounting for $43.6 billion in overall spending in 2020.
Within an interdisciplinary health model, pharmacists have previously demonstrated improvements in care for heart failure (HF) patients.
Additionally, the incorporation of Sodium Glucose Co Transporter 2 inhibitors (SGLT2is) and sacubitril/valsartan into the recently updated treatment pathway purposed by the American College of Cardiology (ACC) has further expanded the opportunity for specialty pharmacists to impact this patient population, by improving access to these novel therapies.
Objectives
The purpose of this investigation was to evaluate the impact a clinical specialty pharmacist embedded within a cardiology clinic had on outcomes among HFrEF patients.
Read about the team's findings by downloading the Outcomes Study below.
Download the abstract: